news
EIDD-2801 proven to prevent SARS-CoV-2 infection in vivo
The drug EIDD-2801 was shown to prevent SARS-CoV-2 replication and infection of cells in a new mouse model containing human lung tissue.
List view / Grid view
Covid-19
news
Novel DNA-based COVID-19 vaccines induce immune responses in mice
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
news
New COVID-19 vaccine elicits strong protective immunity in mice and monkeys
A new MVA-based vaccine has shown success at inducing COVID-19 antibody and T-cell responses in pre-clinical studies.
news
Deletions in SARS-CoV-2 Spike protein drive antibody escape, study shows
Researchers have found that SARS-CoV-2 evades immune responses by deleting parts of its genetic sequence that encode for the Spike protein.
news
COVID-19 vaccine candidate stimulates neutralising antibody production in vivo
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
news
Majority retain COVID-19 antibodies for six months after infection
A study has shown that 88 percent of people infected by COVID-19 were able to produce SARS-CoV-2 antibodies after six months.
news
Thapsigargin could be used as antiviral to treat COVID-19, study shows
Researchers have discovered that thapsigargin has novel antiviral properties and is effective against COVID-19 in pre-clinical studies.
news
Novel AI tool takes a DeepCE dive into potential drugs for COVID-19
A new phenotype-based compound screening technology, called DeepCE, identified 10 compounds that could be repurposed for COVID-19.
news
Novel protein could neutralise SARS-CoV-2 infection in kidneys
A new protein can trick SARS-CoV-2 and bind to the Spike protein rather than cell membranes in a kidney organoid.
news
N439K variant of SARS-CoV-2 is resistant to some neutralising antibodies, shows study
The N439K mutation improves the interaction between SARS-CoV-2 Spike protein and the viral receptor ACE2 and eludes antibody-mediated immunity, say investigators.
news
UK offers genomics expertise to identify new SARS-CoV-2 variants
The UK Government has said genomics expertise will be offered to countries around the world to identify new variants of SARS-CoV-2.
news
Heparin inhibits SARS-CoV-2 invasion, finds study
Research suggests heparin could be repurposed for COVID-19 because it can bind to the SARS-CoV-2 Spike protein and prevent the virus from infecting cells in vitro.
news
T cells target broad range of SARS-CoV-2 epitopes, study shows
A study has found that T cells combat SARS-CoV-2 by targeting many sites on the coronavirus, not just the Spike protein.
news
New database to track neurological symptoms of COVID-19
NeuroCOVID will be a resource of clinical information and biospecimens from people who experience neurological problems associated with SARS-CoV-2 infection.
news
Melatonin could act as barrier against SARS-CoV-2 infection
Researchers have suggested using melatonin in a nasal spray to create a protective barrier against SARS-CoV-2 in pre-symptomatic patients.
